10-K: Orchestra BioMed Reports 2025 Results, Advances Trials

Orchestra BioMed Holdings, Inc. reported a net loss of $52.7 million for 2025, while advancing key clinical trials for its AVIM Therapy and Virtue SAB product candidates and securing new financing.

Summary

• Orchestra BioMed Holdings, Inc. reported a net loss of $52.7 million for the year ended December 31, 2025, an improvement from a $61.0 million net loss in 2024.
• Total revenue significantly increased to $33.48 million in 2025 from $2.64 million in 2024, primarily driven by a $30.9 million increase in partnership revenue.
• Partnership revenue for 2025 included $10.0 million from a Right of First Refusal (ROFR) agreement with Terumo and $7.4 million associated with a premium above the fair market value of Series A Preferred Stock issued to Terumo.
• Research and development expenses rose by 36% to $58.2 million in 2025, up from $42.8 million in 2024, reflecting increased investment in the BACKBEAT and Virtue Trials.
• Selling, general and administrative expenses increased by 12% to $26.9 million in 2025 from $23.9 million in 2024.
• The company had $34.7 million in cash and cash equivalents and $71.8 million in marketable securities as of December 31, 2025, totaling $106.5 million.
• Enrollment for the BACKBEAT global pivotal study for AVIM Therapy is currently planned for completion in mid-2026, and for the Virtue Trial for Virtue SAB in mid-2027.
• The company secured $20.0 million from a convertible loan agreement with Medtronic and expects an additional $15.0 million from Ligand in April 2026.
• Orchestra BioMed expects to receive up to $10.7 million in cash proceeds in 2026 from the acquisition of Vivasure Medical Limited by Haemonetics Corporation, with $4.7 million already received in January 2026.
• The company's common stock is listed on the Nasdaq Global Market under the symbol OBIO, with 58,520,901 shares outstanding as of March 10, 2026.
• The company has an accumulated deficit of $362.6 million as of December 31, 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing with cautious optimism. While the company continues to incur significant losses and faces substantial R&D costs, the progress in pivotal clinical trials, multiple FDA Breakthrough Device Designations, and recent financing activities (Medtronic loan, Ligand payment, Vivasure proceeds) provide a positive outlook for future development and potential commercialization. The termination of the Terumo agreement for Virtue SAB's coronary indications is a setback, but the retention of rights for other vascular indications and the pursuit of new partnerships mitigate this. The reliance on external funding and the inherent risks of clinical development remain key considerations.

Positives

• Net loss improved to $52.7 million in 2025 from $61.0 million in 2024, indicating a reduction in losses.
• Total revenue increased significantly by 1,169% to $33.48 million in 2025, primarily due to partnership revenue from the Terumo ROFR agreement and Series A Preferred Stock issuance.
• Secured $20.0 million in convertible loan from Medtronic and expects an additional $15.0 million from Ligand in April 2026, bolstering liquidity.
• Received $4.7 million upfront from the acquisition of Vivasure Medical by Haemonetics, with potential for up to $6.0 million more in 2026 and future earnouts.
• AVIM Therapy received FDA Breakthrough Device Designation for hypertension in patients with preserved left ventricular systolic function and uncontrolled hypertension with increased ASCVD risk.
• Virtue SAB also received FDA Breakthrough Device Designation for coronary in-stent restenosis, coronary small vessel disease, and peripheral artery disease below-the-knee.
• Initiated patient enrollment for the Virtue Trial (U.S. IDE pivotal study) for Virtue SAB in October 2025.
• First patient enrolled and randomized into the BACKBEAT study for AVIM Therapy in January 2024.
• Long-term (3+ years) data from MODERATO II study demonstrated sustained, clinically meaningful reduction in 24-hour ambulatory systolic blood pressure with AVIM Therapy.
• MODERATO II study retrospective analysis showed favorable impact of AVIM Therapy on Echo markers of diastolic dysfunction, a key driver of heart failure progression.
• The company's partnership-enabled business model aims to accelerate innovation and share risks/rewards with market leaders like Medtronic.

Negatives

• The company continues to incur significant net losses, with an accumulated deficit of $362.6 million as of December 31, 2025.
• Research and development expenses increased substantially by 36% to $58.2 million in 2025, indicating high ongoing costs.
• Product revenue decreased slightly by 3% in 2025, suggesting limited growth in existing commercial products.
• The Terumo Agreement for Virtue SAB was terminated, requiring the company to seek a new strategic partner for coronary artery disease indications.
• The company is highly dependent on partners for commercialization and third-party vendors for manufacturing, introducing supply chain and execution risks.
• The exercise prices of a significant portion of outstanding warrants are currently higher than the market price of common stock, making their exercise unlikely and limiting potential cash proceeds.
• The company's ability to utilize net operating loss carryforwards may be limited by Section 382 of the Internal Revenue Code and other factors.
• The company anticipates needing substantial additional funding to finance operations beyond Q4 2027, with no assurance of availability on acceptable terms.

Risks

• The company has a history of net losses and expects to continue incurring losses for the foreseeable future, with no assurance of achieving or sustaining profitability.
• Ability to timely raise capital in the future may be limited or unavailable on acceptable terms, potentially forcing delays, reductions, or elimination of product development or commercialization efforts.
• The clinical study process is lengthy, expensive, and has uncertain outcomes; unsuccessful or delayed clinical studies could harm the business.
• Failures or perceived failures in clinical studies will delay and may prevent product candidate development and regulatory approval, damaging business prospects and reputation.
• Even with FDA approvals, product candidates may not achieve or maintain market acceptance and may be subject to additional regulatory requirements post-approval.
• The company may be unable to compete successfully with larger companies in highly competitive industries due to greater resources of competitors.
• Sizes of markets for product candidates have not been established with precision and may be smaller than estimated, impacting future sales.
• Interim, top-line, and preliminary data from clinical studies may change as more patient data become available and are subject to audit and verification, potentially resulting in material changes in final data.
• Product candidates may be associated with serious adverse events, undesirable side effects, or other properties that could halt clinical development, prevent regulatory approval, limit commercial potential, or result in negative consequences.
• International sales may face difficulties in obtaining regulatory approval or certification or in successful marketing and distribution.
• Expending limited resources on a particular product or indication may lead to failure to capitalize on more profitable opportunities.
• High dependence on partners for successful marketing and sale of initial product candidates, with no assurance of forming or managing successful partnerships.
• High dependence on partners and third-party vendors for manufacturing and materials, with no redundancy in the supply chain, creating vulnerability to disruptions.
• Limited pharmaceutical manufacturing experience and potential problems or delays from Contract Manufacturing Organizations (CMOs) could limit revenue growth or increase losses.
• Products remain subject to regulatory scrutiny and post-marketing requirements even after approval; failure to comply could lead to enforcement actions or recalls.
• Medical device products may cause or contribute to adverse medical events or malfunctions requiring reporting to regulatory authorities, with sanctions for non-compliance.
• Healthcare cost-containment pressures and reforms could decrease demand, prices, and procedures, adversely affecting the business.
• Information technology systems, or those of third parties, may fail or suffer security/data privacy breaches, leading to costs, revenue loss, liabilities, and operational disruption.
• Inability to effectively protect or enforce intellectual property could have a material adverse effect.
• Inability to protect and control unpatented trade secrets, know-how, and other proprietary technology may result in competitive harm.
• Involvement in litigation or other proceedings related to intellectual property rights could cause substantial costs and liability.
• Need to obtain intellectual property rights from third parties, with no assurance of success or favorable terms.
• Inadequate protection of trademarks and trade names could hinder name recognition and adversely affect the business.
• Future sales, or perception of future sales, of shares by existing stockholders and exercise of registration rights may adversely affect common stock market price.
• Failure to meet Nasdaq's continued listing requirements could result in delisting.
• Changes in tax laws could adversely affect taxes paid and financial results.
• Geopolitical risks and other global events, including trade conflicts and military conflicts, could negatively affect foreign suppliers and operations.

Future Outlook

The company anticipates its cash, cash equivalents, marketable securities, and committed financing will fund operations into the fourth quarter of 2027. It plans to complete enrollment for the BACKBEAT study by mid-2026 and the Virtue Trial by mid-2027. The company may seek additional liquidity through equity issuance or other financing structures earlier than anticipated. It also plans to initiate a pilot clinical study in 2026 for AVIM Therapy in HFpEF patients and explore additional therapeutic applications for SirolimusEFR.

Management Comments

• Management believes AVIM-enabled pacemakers, if commercially approved, have the potential to be rapidly adopted into existing pacemaker-indicated patient care for addressable hypertensive patients.
• Management believes the substantial potential added clinical value and differentiation of AVIM-enabled pacemakers can help Medtronic potentially expand market share and grow revenue.
• Management believes Virtue SAB's performance in the SABRE study, particularly in the single-layer ISR per protocol population, reflects a promising opportunity for Virtue SAB in coronary artery treatment.
• Management believes FreeHold devices are designed to offer several potential advantages over existing retraction options, including improved patient care, full surgeon autonomy, and optimized visualization.
• Management believes the Pure-Vu System is potentially attractive for strategic partnership because it is a proprietary enabling technology that addresses significant unmet needs in a large established global market, its usage fits into current treatment paradigms and is easy enough to use with a relatively short learning curve, and its disposable component has sufficiently high profit margins that provide potential for partnering to enable a revenue sharing arrangement.

Industry Context

StockSavvy.ai notes that Orchestra BioMed operates in highly competitive medical device and pharmaceutical industries, facing larger, well-capitalized competitors like Boston Scientific, Medtronic, and Abbott Laboratories. The company's strategy of forming risk-reward-sharing partnerships with global leaders like Medtronic for AVIM Therapy and its prior engagement with Terumo for Virtue SAB is a key differentiator. The FDA Breakthrough Device Designations for both flagship candidates position them for expedited review and potential favorable reimbursement pathways, which is crucial in a market driven by cost-containment pressures and evolving regulatory landscapes. The termination of the Terumo agreement for Virtue SAB's coronary indications highlights the competitive and dynamic nature of securing commercialization partners in this space, especially against established players with approved products like Boston Scientific's AGENT DCB.

Comparison to Industry Standards

• AVIM Therapy's MODERATO II study showed a statistically significant 11.1 mmHg reduction in mean 24-hour ambulatory systolic blood pressure, compared to a non-significant 3.1 mmHg reduction in the control group, resulting in an 8.1 mmHg difference (p=0.01). This compares favorably to standard medical therapy alone.
• In the MODERATO II study, AVIM Therapy achieved an 85% overall response rate, with approximately 54% of treated patients experiencing an aSBP reduction greater than 10 mmHg, an amount associated with clinically meaningful reduction in heart attack and stroke risk.
• Virtue SAB's SABRE study demonstrated a six-month in-segment Late Lumen Loss (LLL) of 0.12 mm, a positive result compared to the study target of 0.43 mm, and a low 2.8% rate of Target Lesion Failure (TLF) at one-year follow-up in the revised per-protocol population.
• Boston Scientific's AGENT paclitaxel-coated balloon, a direct competitor for coronary ISR, reported a 17.9% overall TLF rate at 1 year follow-up in its US IDE study, which Orchestra BioMed believes is still high and creates an opportunity for Virtue SAB.
• Cordis' Selution SLR sirolimus-coated balloon achieved statistical non-inferiority but numerically inferior results in its SELUTION4ISR study compared to a standard of care control group, with a 13.2% TLF rate in single-layer ISR, equivalent to AGENT DCB results. Virtue SAB aims to demonstrate superior results with its sirolimus-based approach.
• The company's use of sirolimus in Virtue SAB is positioned against paclitaxel-based drug-coated balloons, leveraging the superior safety and efficacy profile of limus-eluting stents over paclitaxel-eluting stents observed in meta-analyses (e.g., significantly lower MACE and target lesion revascularization rates).

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings and is not aware of any pending or threatened legal proceeding against it that would have a material adverse effect on its business, operating results, or financial condition.

Related Party Transactions

• Entities associated with RTW Investments, LP (beneficially owned ~21% of common stock prior to Public Offering) purchased Pre-Funded Warrants exercisable for 3,636,363 shares of common stock in August 2025.
• Perceptive Life Sciences Master Fund, Ltd (beneficially owned ~12% of common stock prior to Public Offering) purchased Pre-Funded Warrants exercisable for 1,500,000 shares of common stock in August 2025.
• Medtronic, Inc. (an affiliate of Medtronic plc) is a strategic partner under the Medtronic Agreement and Medtronic Loan Agreement, and purchased 4,077,427 shares of common stock for $11.2 million in August 2025.
• Terumo Medical Corporation (TMC) entered into a Termination and ROFR Agreement and purchased 200,000 shares of Series A Preferred Stock for $20.0 million in November 2025.
• Vivasure Medical Limited, a company in which Orchestra BioMed held a minority equity interest (approximately 10.9% as of December 31, 2025), was acquired by Haemonetics Corporation in January 2026, resulting in proceeds to Orchestra BioMed.

Stakeholder Impact

• **Shareholders:** Potential for dilution from future equity raises and warrant exercises. Volatility in stock price due to clinical trial results and market perception. Potential for long-term value creation if product candidates achieve commercial success through partnerships.
• **Employees:** Increased headcount and consulting costs reflect growth in R&D and administrative functions. Stock-based compensation is a significant component of employee incentives. Management changes include the adoption of Rule 10b5-1 trading arrangements by key executives.
• **Customers (Hospitals, Physicians):** New product candidates like AVIM Therapy and Virtue SAB aim to improve clinical outcomes and offer distinct commercial advantages. Adoption depends on demonstrating safety, efficacy, cost-effectiveness, and fitting into existing treatment paradigms.
• **Suppliers/Vendors:** High dependence on third-party manufacturers and single-source suppliers for critical components (e.g., sirolimus from China, angioplasty balloons from Singapore) introduces supply chain risks.
• **Partners (Medtronic, Ligand, Terumo):** Medtronic is a key development and commercialization partner for AVIM Therapy, with revenue-sharing arrangements. Ligand provides financing in exchange for future royalty payments. The termination of the Terumo agreement for Virtue SAB's coronary indications necessitates finding new partners for that segment.
• **Regulatory Bodies (FDA, EMA):** The company is subject to extensive and evolving regulatory requirements for medical devices and drug/device combination products, including clinical trial oversight, manufacturing compliance (QMSR, cGMP), and post-marketing surveillance. Breakthrough Device Designations aim to expedite review.

Next Steps

• Continue active screening and enrollment for the BACKBEAT study, with enrollment completion planned for mid-2026.
• Continue patient enrollment for the Virtue Trial, with enrollment completion planned for mid-2027.
• Initiate a pilot clinical study in 2026 for AVIM Therapy for the treatment of patients with Heart Failure with preserved Ejection Fraction (HFpEF).
• Explore additional preclinical work to support new indications for SirolimusEFR.
• Obtain CE Mark approval for the next generation of the Pure-Vu System with both upper and lower GI indications and introduce it to select hospitals in the EU and Israel.
• Increase Pure-Vu System pilot use to approximately 20 U.S. hospitals in 2025, with a focus on the VA system for structured clinical evaluations.
• Seek additional sources of liquidity, potentially through new equity issuance and/or other financing structures, to meet funding requirements beyond Q4 2027.
• Receive $20.0 million from the Medtronic Loan Agreement in April 2026.
• Receive $15.0 million from Ligand pursuant to the Royalty Purchase Agreement in May 2026.
• Receive up to $6.0 million in a first milestone payment from the Vivasure acquisition in 2026, with potential for additional future revenue earnouts.

Key Dates

Recommendation

Orchestra BioMed is in a critical development phase with promising product candidates (AVIM Therapy, Virtue SAB) that have received FDA Breakthrough Device Designations and are progressing through pivotal clinical trials. The recent financing activities and improved net loss for 2025 are positive indicators of operational stability and continued investment in R&D. However, the company still faces significant risks, including substantial ongoing losses, high R&D expenses, reliance on third-party partnerships and manufacturing, and the inherent uncertainties of clinical trial outcomes and regulatory approvals. The termination of the Terumo agreement for a key indication also adds a layer of commercial uncertainty. Given the high-risk, high-reward nature of biomedical innovation and the company's current stage, a 'hold' recommendation is appropriate for seasoned investors. It acknowledges the potential for future growth while recognizing the considerable execution risks and the need for further clarity on clinical trial results and commercialization pathways.

Keywords

BioMed, Medical Devices, Hypertension, AVIM Therapy, Virtue SAB, Sirolimus, Drug-Device Combination, Clinical Trials, FDA Approval, Cardiovascular Disease, Pacemakers, In-Stent Restenosis, Drug-Coated Balloon, Biomedical Innovation, Strategic Partnerships, Medtronic, Ligand Pharmaceuticals, Terumo, Healthcare Technology, Biotechnology